The tRNA primer activation signal in the human immunodeficiency virus type 1 genome is important for initiation and processive elongation of reverse transcription.

PubWeight™: 1.40‹?› | Rank: Top 5%

🔗 View Article (PMC 153804)

Published in J Virol on March 01, 2002

Authors

Nancy Beerens1, Ben Berkhout

Author Affiliations

1: Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, 1100 DE Amsterdam, The Netherlands.

Articles citing this

Structural determinants and mechanism of HIV-1 genome packaging. J Mol Biol (2011) 1.83

Nucleocapsid protein function in early infection processes. Virus Res (2008) 1.53

Whitefly (Bemisia tabaci) genome project: analysis of sequenced clones from egg, instar, and adult (viruliferous and non-viruliferous) cDNA libraries. BMC Genomics (2006) 1.34

Identification of specific HIV-1 reverse transcriptase contacts to the viral RNA:tRNA complex by mass spectrometry and a primary amine selective reagent. Proc Natl Acad Sci U S A (2002) 1.26

RNA structure modulates splicing efficiency at the human immunodeficiency virus type 1 major splice donor. J Virol (2007) 1.22

Identification of a minimal region of the HIV-1 5'-leader required for RNA dimerization, NC binding, and packaging. J Mol Biol (2012) 1.14

Mutations in human immunodeficiency virus type 1 nucleocapsid protein zinc fingers cause premature reverse transcription. J Virol (2008) 1.05

Roles of Gag and NCp7 in facilitating tRNA(Lys)(3) Annealing to viral RNA in human immunodeficiency virus type 1. J Virol (2009) 1.03

Coordinate roles of Gag and RNA helicase A in promoting the annealing of formula to HIV-1 RNA. J Virol (2010) 1.01

Forced selection of a human immunodeficiency virus type 1 variant that uses a non-self tRNA primer for reverse transcription: involvement of viral RNA sequences and the reverse transcriptase enzyme. J Virol (2004) 1.01

In-gel probing of individual RNA conformers within a mixed population reveals a dimerization structural switch in the HIV-1 leader. Nucleic Acids Res (2013) 0.96

Exploring Ty1 retrotransposon RNA structure within virus-like particles. Nucleic Acids Res (2012) 0.95

Structural polymorphism of the HIV-1 leader region explored by computational methods. Nucleic Acids Res (2005) 0.94

Frequent dual initiation in human immunodeficiency virus-based vectors containing two primer-binding sites: a quantitative in vivo assay for function of initiation complexes. J Virol (2004) 0.94

Switching the in vitro tRNA usage of HIV-1 by simultaneous adaptation of the PBS and PAS. RNA (2002) 0.93

Analysis of the contribution of reverse transcriptase and integrase proteins to retroviral RNA dimer conformation. J Virol (2005) 0.89

Defective replication in human immunodeficiency virus type 1 when non-primers are used for reverse transcription. J Virol (2005) 0.88

The availability of the primer activation signal (PAS) affects the efficiency of HIV-1 reverse transcription initiation. Nucleic Acids Res (2007) 0.86

Few mutations in the 5' leader region mediate fitness recovery of debilitated human immunodeficiency type 1 viruses. J Virol (2005) 0.86

Initiation of HIV Reverse Transcription. Viruses (2010) 0.85

A genomic selection strategy to identify accessible and dimerization blocking targets in the 5'-UTR of HIV-1 RNA. Nucleic Acids Res (2004) 0.85

Does the HIV-1 primer activation signal interact with tRNA3(Lys) during the initiation of reverse transcription? Nucleic Acids Res (2003) 0.85

The allosteric HIV-1 integrase inhibitor BI-D affects virion maturation but does not influence packaging of a functional RNA genome. PLoS One (2014) 0.85

Opening of the TAR hairpin in the HIV-1 genome causes aberrant RNA dimerization and packaging. Retrovirology (2012) 0.84

In vivo SELEX of single-stranded domains in the HIV-1 leader RNA. J Virol (2013) 0.84

On the role of four small hairpins in the HIV-1 RNA genome. RNA Biol (2013) 0.82

Alternative tRNA priming of human immunodeficiency virus type 1 reverse transcription explains sequence variation in the primer-binding site that has been attributed to APOBEC3G activity. J Virol (2005) 0.82

On the importance of the primer activation signal for initiation of tRNA(lys3)-primed reverse transcription of the HIV-1 RNA genome. Nucleic Acids Res (2003) 0.81

Eliminating HIV-1 Packaging Sequences from Lentiviral Vector Proviruses Enhances Safety and Expedites Gene Transfer for Gene Therapy. Mol Ther (2017) 0.80

Structure-function relationships of the initiation complex of HIV-1 reverse transcription: the case of mutant viruses using tRNA(His) as primer. Nucleic Acids Res (2003) 0.80

In virio SHAPE analysis of tRNA(Lys3) annealing to HIV-1 genomic RNA in wild type and protease-deficient virus. Retrovirology (2015) 0.80

Synthetic tRNALys,3 as the replication primer for the HIV-1HXB2 and HIV-1Mal genomes. Nucleic Acids Res (2004) 0.79

Role of the primer activation signal in tRNA annealing onto the HIV-1 genome studied by single-molecule FRET microscopy. RNA (2013) 0.79

The Interaction between tRNA(Lys) 3 and the primer activation signal deciphered by NMR spectroscopy. PLoS One (2013) 0.78

DHX9/RHA Binding to the PBS-Segment of the Genomic RNA during HIV-1 Assembly Bolsters Virion Infectivity. J Mol Biol (2016) 0.76

Heterogeneous structures formed by conserved RNA sequences within the HIV reverse transcription initiation site. RNA (2016) 0.75

Reverse Transcription in the Saccharomyces cerevisiae Long-Terminal Repeat Retrotransposon Ty3. Viruses (2017) 0.75

A Fourth Generation Lentiviral Vector: Simplifying Genomic Gymnastics. Mol Ther (2017) 0.75

Articles cited by this

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science (1992) 14.70

Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A (1993) 9.47

Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J (1996) 3.92

Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins: significance for viral replication. Trends Biochem Sci (1998) 3.78

Initiation of reverse transcription of HIV-1: secondary structure of the HIV-1 RNA/tRNA(3Lys) (template/primer). J Mol Biol (1995) 3.23

Interaction between retroviral U5 RNA and the T psi C loop of the tRNA(Trp) primer is required for efficient initiation of reverse transcription. J Virol (1992) 3.06

Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. EMBO J (1998) 2.84

A retroviral RNA secondary structure required for efficient initiation of reverse transcription. J Virol (1988) 2.62

Structure and function of the human immunodeficiency virus leader RNA. Prog Nucleic Acid Res Mol Biol (1996) 2.59

tRNAs as primer of reverse transcriptases. Biochimie (1995) 2.37

Construction of a type 1 human immunodeficiency virus that maintains a primer binding site complementary to tRNA(His). J Virol (1996) 2.30

Specific initiation and switch to elongation of human immunodeficiency virus type 1 reverse transcription require the post-transcriptional modifications of primer tRNA3Lys. EMBO J (1996) 2.24

Point mutations in conserved amino acid residues within the C-terminal domain of HIV-1 reverse transcriptase specifically repress RNase H function. FEBS Lett (1989) 2.20

Simian immunodeficiency virus RNA is efficiently encapsidated by human immunodeficiency virus type 1 particles. J Virol (1993) 2.17

Overlapping retrovirus U5 sequence elements are required for efficient integration and initiation of reverse transcription. J Virol (1991) 2.16

A specific orientation of RNA secondary structures is required for initiation of reverse transcription. J Virol (1994) 2.07

Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase. Methods Enzymol (1995) 2.01

A conserved hairpin motif in the R-U5 region of the human immunodeficiency virus type 1 RNA genome is essential for replication. J Virol (1997) 1.91

An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences. J Virol (1994) 1.81

Initiation of HIV-1 reverse transcription is regulated by a primer activation signal. J Biol Chem (2001) 1.71

Structure-based mutagenesis of the human immunodeficiency virus type 1 DNA attachment site: effects on integration and cDNA synthesis. J Virol (1999) 1.64

Secondary structure of the HIV-2 leader RNA comprising the tRNA-primer binding site. Nucleic Acids Res (1993) 1.61

Structural basis for the specificity of the initiation of HIV-1 reverse transcription. EMBO J (1999) 1.59

Mapping the RNA binding sites for human immunodeficiency virus type-1 gag and NC proteins within the complete HIV-1 and -2 untranslated leader regions. Nucleic Acids Res (1998) 1.55

The role of nucleocapsid and U5 stem/A-rich loop sequences in tRNA(3Lys) genomic placement and initiation of reverse transcription in human immunodeficiency virus type 1. J Virol (1998) 1.47

Comparison of 5' and 3' long terminal repeat promoter function in human immunodeficiency virus. J Virol (1994) 1.41

Initiation of (-) strand DNA synthesis from tRNA(3Lys) on lentiviral RNAs: implications of specific HIV-1 RNA-tRNA(3Lys) interactions inhibiting primer utilization by retroviral reverse transcriptases. Proc Natl Acad Sci U S A (1996) 1.39

The importance of the A-rich loop in human immunodeficiency virus type 1 reverse transcription and infectivity. J Virol (1997) 1.37

Genetic analysis of the U5-PBS of a novel HIV-1 reveals multiple interactions between the tRNA and RNA genome required for initiation of reverse transcription. RNA (1998) 1.34

Hydroxyl radical footprint analysis of human immunodeficiency virus reverse transcriptase-template.primer complexes. Proc Natl Acad Sci U S A (1993) 1.32

Restoration of tRNA3Lys-primed(-)-strand DNA synthesis to an HIV-1 reverse transcriptase mutant with extended tRNAs. Implications for retroviral replication. J Biol Chem (1996) 1.26

Interaction of retroviral reverse transcriptase with template-primer duplexes during replication. Prog Nucleic Acid Res Mol Biol (1998) 1.23

Multiple biological roles associated with the Rous sarcoma virus 5' untranslated RNA U5-IR stem and loop. J Virol (1997) 1.14

Nucleotide substitutions within U5 are critical for efficient reverse transcription of human immunodeficiency virus type 1 with a primer binding site complementary to tRNA(His). J Virol (1997) 1.11

An expanded model of replicating human immunodeficiency virus reverse transcriptase. Biochemistry (1995) 1.08

Mutational analysis of the tRNA3Lys/HIV-1 RNA (primer/template) complex. Nucleic Acids Res (1998) 1.08

HIV-1 RNA editing, hypermutation, and error-prone reverse transcription. Science (2001) 1.08

Dynamics of the HIV-1 reverse transcription complex during initiation of DNA synthesis. J Biol Chem (2000) 1.06

Changes in Rous sarcoma virus RNA secondary structure near the primer binding site upon tRNATrp primer annealing. J Virol (1999) 1.04

Initiation of HIV-2 reverse transcription: a secondary structure model of the RNA-tRNA(Lys3) duplex. Nucleic Acids Res (2001) 1.03

Stabilization of the U5-leader stem in the HIV-1 RNA genome affects initiation and elongation of reverse transcription. Nucleic Acids Res (2000) 0.99

Mutations within the primer binding site of the human immunodeficiency virus type 1 define sequence requirements essential for reverse transcription. Virology (1996) 0.99

Mechanistic studies of early pausing events during initiation of HIV-1 reverse transcription. J Biol Chem (1998) 0.98

Articles by these authors

(truncated to the top 100)

Identification of a new human coronavirus. Nat Med (2004) 11.24

Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52

Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol (2002) 3.59

Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 3.23

HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res (2005) 2.93

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS (2004) 2.51

Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther (2006) 2.48

The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog (2007) 2.48

Suppression of RNA interference by adenovirus virus-associated RNA. J Virol (2005) 2.29

A novel pancoronavirus RT-PCR assay: frequent detection of human coronavirus NL63 in children hospitalized with respiratory tract infections in Belgium. BMC Infect Dis (2005) 2.28

Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A (2005) 2.21

Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther (2008) 2.14

RNA interference against viruses: strike and counterstrike. Nat Biotechnol (2007) 2.14

Viral evolution as a tool to improve the tetracycline-regulated gene expression system. J Biol Chem (2004) 2.06

In HIV-1 pathogenesis the die is cast during primary infection. AIDS (2007) 2.04

Croup is associated with the novel coronavirus NL63. PLoS Med (2005) 2.03

Detection of new viruses by VIDISCA. Virus discovery based on cDNA-amplified fragment length polymorphism. Methods Mol Biol (2008) 1.95

Retroviral superinfection resistance. Retrovirology (2005) 1.82

A novel long distance base-pairing interaction in human immunodeficiency virus type 1 RNA occludes the Gag start codon. J Biol Chem (2002) 1.81

Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. J Virol (2002) 1.78

Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies. J Virol (2002) 1.75

The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle. J Virol (2003) 1.71

Inhibition of virus replication by RNA interference. J Biomed Sci (2003) 1.70

Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res (2008) 1.65

Factor correction as a tool to eliminate between-session variation in replicate experiments: application to molecular biology and retrovirology. Retrovirology (2006) 1.64

Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol (2004) 1.64

Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol (2008) 1.61

The novel human coronaviruses NL63 and HKU1. J Virol (2006) 1.59

Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol (2004) 1.53

Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol (2007) 1.52

Multiple secondary structure rearrangements during HIV-1 RNA dimerization. Biochemistry (2002) 1.50

Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference. J Virol (2007) 1.50

Microprocessor, Setx, Xrn2, and Rrp6 co-operate to induce premature termination of transcription by RNAPII. Cell (2012) 1.49

Mosaic structure of human coronavirus NL63, one thousand years of evolution. J Mol Biol (2006) 1.40

Proteomic studies reveal coordinated changes in T-cell expression patterns upon infection with human immunodeficiency virus type 1. J Virol (2008) 1.40

Genome structure and transcriptional regulation of human coronavirus NL63. Virol J (2004) 1.39

Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology (2013) 1.37

Human coronavirus NL63, a new respiratory virus. FEMS Microbiol Rev (2006) 1.37

Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology (2010) 1.36

The HIV-1 leader RNA conformational switch regulates RNA dimerization but does not regulate mRNA translation. Biochemistry (2005) 1.36

Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner. J Virol (2004) 1.34

Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4+ T lymphocytes. J Clin Invest (2005) 1.34

Lack of detection of XMRV in seminal plasma from HIV-1 infected men in The Netherlands. PLoS One (2010) 1.34

Deep sequencing of virus-infected cells reveals HIV-encoded small RNAs. Nucleic Acids Res (2011) 1.32

A miRNA-tRNA mix-up: tRNA origin of proposed miRNA. RNA Biol (2010) 1.30

A riboswitch regulates RNA dimerization and packaging in human immunodeficiency virus type 1 virions. J Virol (2004) 1.30

Human parechovirus type 1, 3, 4, 5, and 6 detection in picornavirus cultures. J Clin Microbiol (2007) 1.28

A systematic analysis of the effect of target RNA structure on RNA interference. Nucleic Acids Res (2007) 1.27

Dimerization and template switching in the 5' untranslated region between various subtypes of human immunodeficiency virus type 1. J Virol (2003) 1.26

Comparison of single regulated lentiviral vectors with rtTA expression driven by an autoregulatory loop or a constitutive promoter. Nucleic Acids Res (2005) 1.23

Differential susceptibility of naïve, central memory and effector memory T cells to dendritic cell-mediated HIV-1 transmission. Retrovirology (2006) 1.23

The TAR hairpin of human immunodeficiency virus type 1 can be deleted when not required for Tat-mediated activation of transcription. J Virol (2007) 1.22

RNA structure modulates splicing efficiency at the human immunodeficiency virus type 1 major splice donor. J Virol (2007) 1.22

Selection of T1249-resistant human immunodeficiency virus type 1 variants. J Virol (2008) 1.21

Sialoadhesin (CD169) expression in CD14+ cells is upregulated early after HIV-1 infection and increases during disease progression. PLoS One (2007) 1.21

The virion-associated incoming HIV-1 RNA genome is not targeted by RNA interference. Retrovirology (2006) 1.20

Regulated HIV-2 RNA dimerization by means of alternative RNA conformations. Nucleic Acids Res (2002) 1.20

Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr (2008) 1.20

Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands. PLoS One (2009) 1.20

Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J Gen Virol (2006) 1.19

Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN--gp120 interaction. J Virol (2005) 1.19

RNAi suppressors encoded by pathogenic human viruses. Int J Biochem Cell Biol (2008) 1.18

Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. Mol Ther (2009) 1.18

Effects of random mutations in the human immunodeficiency virus type 1 transcriptional promoter on viral fitness in different host cell environments. J Virol (2006) 1.16

Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One (2009) 1.16

HIV-1 latency in actively dividing human T cell lines. Retrovirology (2008) 1.16

The NS3 protein of rice hoja blanca virus complements the RNAi suppressor function of HIV-1 Tat. EMBO Rep (2009) 1.13

Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J Infect Dis (2012) 1.13

Inhibition of HIV-1 by fusion inhibitors. Curr Pharm Des (2010) 1.13

Probing alternative foldings of the HIV-1 leader RNA by antisense oligonucleotide scanning arrays. Nucleic Acids Res (2004) 1.12

Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J Biol Chem (2009) 1.11

SHAPE-directed discovery of potent shRNA inhibitors of HIV-1. Mol Ther (2012) 1.11

The biased nucleotide composition of the HIV genome: a constant factor in a highly variable virus. Retrovirology (2012) 1.10

Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. J Virol (2008) 1.10

The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. Retrovirology (2008) 1.10

Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. J Virol (2011) 1.09

Triple HIV-1 infection. N Engl J Med (2005) 1.09

RNAi and cellular miRNAs in infections by mammalian viruses. Methods Mol Biol (2011) 1.08

Survey of the temporal changes in HIV-1 replicative fitness in the Amsterdam Cohort. Virology (2007) 1.08

Antibacterial and antiviral effects of milk proteins and derivatives thereof. Curr Pharm Des (2003) 1.08

Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob Agents Chemother (2006) 1.07

Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site. J Virol (2006) 1.07

Design of extended short hairpin RNAs for HIV-1 inhibition. Nucleic Acids Res (2007) 1.06

Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure. AIDS Res Hum Retroviruses (2004) 1.06

Dicer-independent processing of short hairpin RNAs. Nucleic Acids Res (2013) 1.06

The HIV RNA setpoint theory revisited. Retrovirology (2007) 1.06

A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs. J RNAi Gene Silencing (2005) 1.06

HIV-1 drug-resistance and drug-dependence. Retrovirology (2007) 1.05

Long-term inhibition of HIV-1 replication with RNA interference against cellular co-factors. Antiviral Res (2010) 1.05

Anticipating and blocking HIV-1 escape by second generation antiviral shRNAs. Retrovirology (2010) 1.05

A conditionally replicating virus as a novel approach toward an HIV vaccine. Methods Enzymol (2004) 1.05

Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function. J Virol (2011) 1.04

Opposing roles of blood myeloid and plasmacytoid dendritic cells in HIV-1 infection of T cells: transmission facilitation versus replication inhibition. Blood (2006) 1.04

An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection. J Virol (2012) 1.04

Identification of new human coronaviruses. Expert Rev Anti Infect Ther (2007) 1.04

HIV-1 reverse transcription initiation: a potential target for novel antivirals? Virus Res (2008) 1.03

Dendritic cell-mediated HIV-1 transmission to T cells of LAD-1 patients is impaired due to the defect in LFA-1. Retrovirology (2006) 1.03

Occult hepatitis B infection: an evolutionary scenario. Virol J (2008) 1.03

Optimization of shRNA inhibitors by variation of the terminal loop sequence. Antiviral Res (2010) 1.03

APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations. AIDS (2004) 1.02